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Abstract
BAD, a pro-apoptotic protein of the Bcl-2 family, has recently been identified as an integrator of several anti-apoptotic
signaling pathways in prostate cancer cells. Thus, activation of EGFR, GPCRs or PI3K pathway leads to BAD phosphorylation
and inhibition of apoptosis. Increased levels of BAD in prostate carcinomas have also been reported. It appears
contradictory that instead of limiting expression of pro-apoptotic protein, prostate cancer cells choose to increase BAD
levels while keeping it under tight phosphorylation control. Analysis of the effect of BAD on prostate cancer xenografts has
shown that increased BAD expression enhances tumor growth, while knockdown of BAD expression by shRNA inhibits
tumor growth. Tissue culture experiments demonstrated that increased BAD expression stimulates proliferation of prostate
cancer cells. These results suggest that increased expression of BAD provides a proliferative advantage to prostate tumors,
while BAD dephosphorylation increases sensitivity of prostate cancer cells to apoptosis. Combination of proliferative and
apoptotic properties prompts prostate cancer cells to be ‘‘addicted’’ to increased levels of phosphorylated BAD. Thus,
kinases that phosphorylate BAD are plausible therapeutic targets; while monitoring BAD phosphorylation could be used to
predict tumor response to treatments.
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Introduction
Prostate cancer is the most frequently diagnosed cancer and the
second leading cause of cancer-related deaths in men in the United
States [1]. Currently there is no effective treatment for androgen-
independent advanced prostate cancer [2]. Mechanisms that enable
prostate cancer cells to evade apoptosis may contribute to
therapeutic resistance. Thus, increased levels of several growth
factors, including FGF, EGF, IL-6 and GPCR agonists that activate
anti-apoptotic signaling pathways, have been reported in androgen-
independent prostate cancer [3–7]. Anti-apoptotic signals could
either post-translationally modify apoptosis regulatory proteins or
change their expression levels. Indeed, increased expression of anti-
apoptotic Bcl-2 proteins as well as inhibitors of apoptosis proteins
(IAPs)inadvanced prostate cancerhas been reported [8,9].Also,we
have recently shown that in prostate cancer cells, the pro-apoptotic
Bcl-2 protein BAD plays a unique role as a convergence point of
several anti-apoptotic signaling pathways that include constitutively
active PI3K, activated EGFR and GPCR [6].
BAD, bcl-xl/bcl-2- antagonist causing cell death, was initially
identified in a yeast two hybrid screen interacting with Bcl-2 or Bcl-xl
[10]. BAD is a unique BH3-only family member in that its regulation
is primarily mediated through its conserved phosphorylation sites
(serines 112, 136, and 155 based on the mouse sequence)[11,12].
Phosphorylated BAD fails to bind Bcl-XL or Bcl-2 proteins, and has
been considered an apoptosis sentinel inactivated by anti-apoptotic
signals. Upon withdrawal of survival factors BAD becomes
dephosphorylated, shifts the balance of pro- and anti-apoptotic Bcl
proteins that triggers release of cytochrome c, SMAC and AIF from
mitochondria and subsequently leads to apoptosis [12]. Thereby, it
would not be surprising if cancer cells decrease BAD expression.
A recent study has shown that BAD expression is elevated in
prostatic carcinomas compared to low expression in normal
prostatic epithelium [13]. It seems counterintuitive that prostate
cells would dedicate extra resources to maintain BAD phosphor-
ylation instead of eliminating its expression. It is possible that in
addition to regulating apoptosis, BAD might play a positive role in
prostatic tumor growth.
Here we report that increased BAD expression stimulates
proliferation of prostate cancer cells in tissue culture and prostate
tumor growth in vivo. At the same time, BAD dephosphorylation
increases sensitivity of prostate cancer cells to apoptosis. This
combination of proliferative and apoptotic properties creates
conditions for prostate cancer cells ‘‘addiction’’ to increased levels
of phosphorylated BAD. Thus, kinases that phosphorylate BAD
are plausible therapeutic targets.
Materials and Methods
Cell lines
Prostate cancer cell lines, LNCaP and C4-2, were gifts from Dr.
Leland Chung (Emory University, Atlanta GA). C4-2BADLuc
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(HA-BAD-pTRE2hygro) and firefly luciferase (PGL3) whereas
pTRE2hygro and firefly luciferase (PGL3) were transfected into
C4-2 cells to generate C4-2Luc. LNCaP cells were maintained
with T-medium supplemented with 5% fetal bovine serum, and
C4-2 cells were maintained with RPMI 1640 with 10% fetal
bovine serum. All cells were kept at 5% CO2 at 37uC.
Antibodies and Other Reagents
Antibodies were obtained from the following sources: BAD,
phospho-specific BAD (serines 112, 136, 155) from Cell Signaling
Technology (Beverly, MA); ERK from Zymed Laboratories
(South San Francisco, CA); secondary horseradish peroxidase-
conjugated antibodies used for Western blots from Amersham
Biosciences (Piscataway, NJ). All other chemicals (unless specified)
were purchased from Sigma (St. Louis, MO). Tissue culture
reagents were purchased from Invitrogen (Carlsbad, CA).
shRNA experiments
A lentiviral vector (pLL3.7) [14] was used with an shRNA insert
of annealed oligonucleotides. The BAD DNA target sequences
used were 59-TGAAGGGACTTCCTCGCCCGT-39 and 59
GGCTTGGTCCCATCGGAAG-39. HEK 293 cells were trans-
fected with pLL3.7 vector containing either of these sequences or a
scrambled sequence 59-GGTACGGTCAGGCAGCTTCT-39 in
combination with packaging vectors (VSVG, RSV-REV, and
pMDL g/p RRE). After 48 h, supernatants were collected from
these cells and used to infect LNCaP or C4-2 cells [6]. Forty-eight
hours after infection, cells were plated for subsequent experiments.
Proliferation Assays
Cell counts were done by the following: 2610
5 cells were plated
in six cm dishes for each experimental group. The initial cell count
was 24 hours after cells had attached to the dishes (Day 1). Two
additional counts were made three days later (Day 4) and six days
later (Day 7) and then compared to the initial cell count. Counts
were made by trypsinizing and collecting cells in media, then
manually counting on a hemacytometer. MTT assays were done
according to instructions of kit manufacturer (Roche Applied
Science, Indianapolis, IN) on cells plated in 24 –well plates at
varying densities. Triplicate wells were used for each data point.
Immunohistochemistry
Antibody staining was performed on histological sections of
formalin-fixed prostate tumor xenografts. Antigen retrieval was
performed by heating slides at 95uC in 10 mM sodium citrate
buffer (pH 6.0) for 60 min. Then, sections were treated identically
as follows: 1) incubated in 2% hydrogen peroxide to block
endogenous peroxidase activity; 2) incubated with blocking
solution: 1% BSA, 0.1% tween20 in PBS (30 min, 25uC); 3)
incubated with primary antibodies, Ki-67 from Abcam Inc.
(Cambridge, MA) diluted 1:25–1:200 in blocking solution
(overnight, 4uC); primary antibodies were followed by peroxidase
conjugated anti-rabbit secondary antibodies (10 mg/ml, in block-
ing solution, 30 min, 25uC) and revealed with 3-39-diaminobenzi-
dine (DAB) as the developing chromogen. Between steps,
specimens were washed in PBS 3 times.
Subcutaneous Implantations
Nude mice (BALB/cAnNCrj-nu from Charles River) received
four subcutaneous injections of 2610
6 cells with Matrigel.
Injections were made using an insulin syringe and a 27 gauge
needle. All manipulations with animals were conducted in humane
manner, in strict adherence with a protocol approved by
institutional ACUC, which was designed to minimize animal
suffering.
Luminescence Imaging
Tumor growth was analyzed with a Xenogen IVISH 100 optical
imaging system (Caliper Life Sciences, Hopkinton, MA). Animals
were immobilized for substrate injection and imaging through an
attached gas anesthesia system consisting of 2% isoflurane/O2.T o
account for background and nonspecific luminescence, mice were
imaged before injection of luciferase. Animals were injected with
100 ml of the firefly luciferase substrate luciferin (3.5 mg/ml in
PBS) and imaged 15 minutes later in prone and supine positions (5
minutes each). Whole-body images were obtained using the Living
ImageH software provided with imaging system. A gray-scale
photographic image and the bioluminescent color image are
superimposed to provide anatomic registration of the light signal.
A region of interest (ROI) was manually selected over the
luminescent signal, and the intensity was recorded as photons/
second within an ROI.
Statistical analysis
To determine whether differences between data sets were
statistically significant, Student’s t-test analysis (two-tailed distri-
bution; two-sample unequal variance) was performed using Excel
software.
Results
BAD expression stimulates proliferation of prostate
cancer cells
Reports on increased expression of BAD in prostate cancer led
us to suggest that prostate cancer cells may benefit from
maintaining BAD expression. To address the possible role of
increased BAD expression, we examined proliferation of prostate
cancer cells that overexpress BAD. For this purpose, we compared
proliferation of cell lines that ectopically express BAD and cell
lines transfected with empty vector. Cells with elevated levels of
BAD were characterized by increased proliferation in tissue
culture (Fig. 1A, B). To exclude the possibility that increased
proliferation of cells that stably express BAD was due to clonal
variations, we compared proliferation in cells transiently trans-
fected with either BAD or empty vector. These experiments
showed increased proliferation in several cell lines that transiently
express BAD (Fig. 1C).
Since C4-2 cells are derived from metastatic prostate cancer
[15], it is possible that they may have already established optimal
levels of BAD. Therefore, we examined the effect of knocking
down BAD expression on proliferation of these cells. C4-2Luc cells
were infected with lentiviral vectors that encode scrambled shRNA
or BAD shRNA. Reduced expression of BAD led to decreased
proliferation of C4-2 cells (Fig. 1D, E).
BAD expression stimulates prostate tumor growth
Experiments in tissue culture have shown that expression of
BAD stimulates division of prostate cancer cells as well as other
cancer cells. To determine whether increased expression levels of
BAD stimulate prostate tumor growth in vivo, we compared growth
of C4-2Luc and C4-2LucBAD cells implanted in immunocom-
promised mice. C4-2Luc and C4-2LucBAD cells express firefly
luciferase that allows the monitoring of xenograft growth
noninvasively by optical imaging. Measuring luminescence instead
of physical tumor size permits detection of xenograft growth prior
to the appearance of palpable subcutaneous tumors. This
BAD Is Good for Tumor Growth
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growth. Analysis of luminescence of C4-2Luc and C4-2LucBAD
xenografts showed increased tumor take and faster tumor growth
of C4-2LucBAD xenografts (Fig. 2AB). Consistent with results of
luminescence analysis, C4-2LucBAD cells produced palpable
tumors at higher frequency comparing to C4-2Luc cells (Fig. 2C).
In accordance with the faster growth of C4-2LucBAD xenografts,
immunohistochemical analysis showed an increased number of
cells that stained positive for the proliferative marker Ki-67
compared to C4-2Luc xenografts (Fig. 2D).
Knockdown of BAD expression by shRNA inhibits tumor
growth
Parallel to experiments with C4-2LucBAD cells, experiments
were conducted with C4-2Luc cells in which endogenous BAD
expression was inhibited by the shRNA approach. C4-2Luc cells
were infected with the lentiviral vector pLL3.7 that expressed
BAD shRNA or scrambled shRNA, and the cells were then
implanted subcutaneously into nude mice. Luminescence of C4-
2Luc xenografts was followed for one week as shown in Fig. 3. C4-
2Luc xenografts with a reduced expression of BAD showed
reduced tumor take and grew at a slower rate than cells with intact
BAD expression.
Discussion
The novel role of BAD in promoting tumor growth
The results presented in this paper show that BAD, the BH-3
only Bcl-2 protein, might function in a dual capacity in prostate
cancer. When dephosphorylated, BAD promotes apoptosis [11],
while in a phosphorylated form it stimulates proliferation and
tumor growth in vivo. This connection between BAD expression
Figure 1. BAD expression increases proliferation of prostate cancer cells. (A) HA-BAD expression in C4-2LucBAD clone. (B) C4-2LucBAD
cells proliferate at a faster rate than C42 cells. C4-2LucBAD cells or C4-2Luc cells were plated in triplicate 6 cm dishes. At days 1 and 4 after plating,
cells were trypsinized and counted. Results at 4 days were significantly different with a p value of ,0.001. Comparable results were obtained in
experiments in which proliferation was measured with the MTT assay. C) Transient expression of HA-BAD stimulates proliferation. LNCaP cells were
transfected with 9:1 mixture of GFP and either of HA-BAD or empty expression vector. Seven days after transfection, the number of GFP positive cells
was counted. Graph shows the HA-BAD/empty vector ratio of GFP positive cells. Proliferation of GFP-positive cells was confirmed by time lapse video
recording. D) Knocking down BAD expression with shRNA decreases proliferation. A lentiviral vector (pLentiLox 3.7) with a BAD shRNA insert was
used to infect C42cells. C4-2Luc cells were plated in triplicate 6 cm dishes. At day 1 and 4 after plating, cells were trypsinized and counted.
Experiments were repeated at least 3 times. E) Western blot analysis of BAD expression in cells infected with empty lentiviral vector, scrambled shRNA
or BAD-specific shRNA. Expression of total ERK was used as loading control.
doi:10.1371/journal.pone.0006224.g001
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6
C4-2Luc or C4-2LucBAD cells. A) Representative whole body images of the animals obtained at 1 day and 2 weeks after implantations using the
IVIS100 and Living ImageH software (Xenogen). B) Dot plot showing fold increase and median luminescence in mice injected with C4-2Luc and C4-
2LucBAD cells. C) Percent of palpable tumors (over 5 mm) developed at injection sites. D) Representative tissue sections of formalin-fixed tumors
stained for proliferation marker Ki67.
doi:10.1371/journal.pone.0006224.g002
Figure 3. Knocking down of BAD expression with shRNA inhibits growth of prostate cancer xenografts. Nude mice received two
subcutaneous injections of 2610
6 C4-2Luc cells infected with lentiviral vector with BAD shRNA (right side) or an empty vector (left side). Images and
quantification are as in Figure 2. A) Representative images of C4-2Luc and C4-2LucBAD tumors. B) Dot plot shows the ratio between luminescence at
one week/day 1. After eight weeks, palpable tumors were detected only at sites injected with C4-2Luc cells infected with empty vector.
doi:10.1371/journal.pone.0006224.g003
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expression of phosphorylated BAD protein in prostate tumors.
Recently, several studies have shown that functions of BAD may
extend beyond sensitizing cells to apoptosis. For instance,
publications from the Peter Vogt and Elizabeth Yang laboratories
have suggested that BAD protein can be involved in promoting
cell cycle progression [16,17]. Thus, fibroblasts with increased
expression of Bcl-2/BclXL are characterized by reduced apoptosis
and also by decreased proliferation. However, when Bcl-2 or
BclXL forms a heterodimeric complex with BAD, cells can
overcome the G0/G1 growth arrest and enter into S phase
[17,18]. These findings were extended to T cells by showing that
T-cells over-expressing BAD were more likely to remain in S-
phase [19].
In other recent reports, BAD in the phosphorylated form was
found to promote assembly of active glucokinase complexes, an
initial step of the glycolytic pathway [20,21]. Although both
increased proliferation and glycolysis are hallmarks of tumor
growth, the experimental evidence that connects BAD expression
with tumor growth has been lacking.
Could BAD play a dual role in prostate cancer
cells?. Several reports have shown that cells that express BAD
proliferate faster; however, mechanistic details on how BAD
promotes proliferation diverge. One possibility is that BAD
provides a counterbalance for increased levels of BclXL and Bcl-
2 that are known to slow proliferation [22]. If this scenario is
correct, any pro-apoptotic Bcl2/BclXL antagonist would be
expected to have a BAD-like effect. However, if expression of
such an antagonist is constitutive, it would defeat the purpose of
increased Bcl-2/BclXL expression by increasing apoptosis
sensitivity. Since the proportion of BAD that could form
heterodimers with anti-apoptotic counterparts depend on
phosphorylation status, BAD may be uniquely suited for the role
of modulator of BCl2/BClXL, availability of which is fine tuned
by protein kinases. It is also possible that by increasing rate of
glucose utilization, BAD expression provides competitive
advantage to the cells in hypoxic tumors that switch from
oxidative phosphorylation to glycolysis [23].
The precise mechanism of how Bcl proteins regulate prolifer-
ation is obscure. It remains to be determined whether a single
mechanism plays a dominant role or BAD-dependent stimulation
of proliferation is mediated via several mechanisms simultaneous-
ly, and whether BAD localization to a specific organelle (e.g.
mitochondria, ER, nuclear envelope) is important. Also, this
positive effect on cell division may not be uniformly manifested in
all cancer cells. Thus, BAD reportedly inhibits G1 to S transition
in MCF7 breast cancer cells [24]. Until the effects of BAD on
proliferation are dissected on a molecular level, we remain with
the notion that effects of BAD expression on proliferation are cell
type-dependent.
Conclusions
Regardless of the exact mechanism that permits BAD to
stimulate tumor growth, this capacity may provide selective
pressure to increase BAD expression in tumors. Activation of
protein kinases that phosphorylate BAD creates a permissive
condition to increased expression of BAD. It is tempting to
speculate that that high BAD expression should make these tumors
increasingly sensitive to inhibitors of signaling pathways that
control BAD. If so, high levels of phosphorylated BAD could be
used to identify patients who will benefit from therapy with such
inhibitors. Future studies in animal models and analysis of clinical
trials data with regard to BAD expression/phosphorylation are
needed to determine the translational value of extensive efforts
spent studying protein kinases that phosphorylate BAD.
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